Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
1997-11-3
|
pubmed:abstractText |
In this study 22 patients with metastatic adenocarcinoma of the cervix were treated with a weekly bolus injection of 4'-epidoxorubicin at a dose of 12 mg/m2. Seventeen patients had received prior radiotherapy, all patients were chemo-naive. Toxicity was generally absent or very mild. One patient had a complete response and 2 patients had a partial response, one was an unconfirmed partial response, giving a response rate of 14%. Six patients had stable disease. The median progression-free survival and overall survival was 2.8 months and 6.1 months, respectively. In conclusion, 4'-epidoxorubicin used at this dosage and schedule has minimal activity in metastatic adenocarcinoma of the cervix.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0959-8049
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
33
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1513-5
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:9337698-Adenocarcinoma,
pubmed-meshheading:9337698-Adult,
pubmed-meshheading:9337698-Aged,
pubmed-meshheading:9337698-Antibiotics, Antineoplastic,
pubmed-meshheading:9337698-Disease-Free Survival,
pubmed-meshheading:9337698-Drug Administration Schedule,
pubmed-meshheading:9337698-Epirubicin,
pubmed-meshheading:9337698-Female,
pubmed-meshheading:9337698-Humans,
pubmed-meshheading:9337698-Middle Aged,
pubmed-meshheading:9337698-Survival Rate,
pubmed-meshheading:9337698-Uterine Cervical Neoplasms
|
pubmed:year |
1997
|
pubmed:articleTitle |
Phase II study of weekly 4'-epidoxorubicin in patients with metastatic adenocarcinoma of the cervix: an EORTC Gynaecological Cancer Cooperative Group study.
|
pubmed:affiliation |
Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek), The Netherlands.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Multicenter Study,
Clinical Trial, Phase II
|